Key factors
sym | MYL |
exch | US |
MCap | 8.586B |
Beta | 1.465 |
PE Ratio | 30.72 |
EPS | 0.516 |
Div date | 2007-06-27 |
Yesterday
sym | MYL |
exch | US |
close | 0.079 |
50 Day MA | 16.42 |
200 Day MA | 16.11 |
Target Price | 21.75 |
Market Cap Mln | 8586.21 |
Share statistics
Shares Outstanding | 541.54M |
Shares Float | 538.05M |
Percent Institutions | 90.49 |
PercentInsiders | 0.912 |
SharesShort | 47.14M |
Short Ratio | 11.15 |
Shares Short Prior Month | 46.48M |
Short Percent | 11.05 |
Income
Revenue TTM | 11.51B |
Revenue Per Share TTM | 22.28 |
Quarterly Revenue Growth YOY | 0.400 |
Gross Profit TTM | 4.551B |
EBITDA | 3.512B |
Diluted Eps TTM | 0.516 |
Quarterly Earnings Growth YOY | -2.30 |
earning
Operating Margin TTM | 0.157 |
PEGRatio | 1.59 |
Trailing PE | 30.72 |
EPS Estimate Current Quarter | 1.16 |
EPS Estimate Current Year | 4.58 |
EPS Estimate Next Quarter | 1.33 |
EPS Estimate Next Year | 4.68 |
Earnings Share | 0.516 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 2003-10-09 |
Last Split Factor | 3:2 |
business
Enterprise Value Ebitda | 11.86 |
Enterprise Value Revenue | 2.799 |
Book Value /share | 24.27 |
Price Book MRQ | 1.635 |
Price Sales TTM | 0.767 |
ProfitMargin | 0.023 |
ReturnOnAssetsTTM | 0.036 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Pharmaceuticals |
Gic Sector | Health Care |
Gic Sub Industry | Pharmaceuticals |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Codes
ISIN | USN594651093 |
CIK | 1623613 |
Code | MYL |
CUSIP | 628530107 |
Employer Id Number | 98-1189497 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2021-01-17 |
is Delisted | 1 |
Delisted Date | 2020-11-19 |
Home Category | Domestic |
info
Fiscal Year End | December |
ForwardPE | 3.776 |
Full Time Employees | 35000 |
IPODate | 1987-12-18 |
International Domestic | International Domestic |
MostRecent Quarter | 2020-09-30 |
Contact
Name | Viatris Inc |
Address | Building 4, Hatfield, United Kingdom, AL10 9UL |
Country Name | USA |
Phone | 44 1707 853 000 |
Web URL | www.mylan.com |
Logo URL | /img/logos/US/Myl.png |
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.